Precription Digita Thraputic for Atients with Nsomnia ( a Protocol for a Pragmatic Randomised Controlled Trial

Overview

Journal BMJ Open

Specialty General Medicine

Date 2022 Aug 8

PMID 35940841

Authors

Rachel P Dreyer

Alyssa Berkowitz

Henry Klar Yaggi

Lynelle Schneeberg

Nilay D Shah

Lindsay Emanuel

Bhanuprakash Kolla

Molly Moore Jeffery

Mark Deeg

Keondae Ervin

Frances Thorndike

Joseph S Ross

Affiliations

Soon will be listed here.

Abstract

Introduction: Cognitive behavioural therapy for insomnia (CBT-I) is effective at treating chronic insomnia, yet in-person CBT-I can often be challenging to access. Prior studies have used technology to bridge barriers but have been unable to extensively assess the impact of the digital therapeutic on real-world patient experience and multidimensional outcomes. Among patients with insomnia, our aim is to determine the impact of a prescription digital therapeutic (PDT) (PEAR-003b, FDA-authorised as Somryst; herein called PDT) that provides mobile-delivered CBT-I on patient-reported outcomes (PROs) and healthcare utilisation.

Methods And Analysis: We are conducting a pragmatically designed, prospective, multicentre randomised controlled trial that leverages Hugo, a unique patient-centred health data-aggregating platform for data collection and patient follow-up from Hugo Health. A total of 100 participants with insomnia from two health centres will be enrolled onto the Hugo Health platform, provided with a linked Fitbit (Inspire 2) to track activity and then randomised 1:1 to receive (or not) the PDT for mobile-delivered CBT-I (Somryst). The primary outcome is a change in the insomnia severity index score from baseline to 9-week postrandomisation. Secondary outcomes include healthcare utilisation, health utility scores and clinical outcomes; change in sleep outcomes as measured with sleep diaries and a change in individual PROs including depressive symptoms, daytime sleepiness, health status, stress and anxiety. For those allocated to the PDT, we will also assess engagement with the PDT.

Ethics And Dissemination: The Institutional Review Boards at Yale University and the Mayo Clinic have approved the trial protocol. This trial will provide important data to patients, clinicians and policymakers about the impact of the PDT device delivering CBT-I on PROs, clinical outcomes and healthcare utilisation. Findings will be disseminated to participants, presented at professional meetings and published in peer-reviewed journals.

Trial Registration Number: NCT04909229.

Citing Articles

Human centered design of AI-powered Digital Therapeutics for stress prevention: Perspectives from multi-stakeholders' workshops about the SHIVA solution.

Bolpagni M, Pardini S, Gabrielli S Internet Interv. 2024; 38:100775.

PMID: 39314669 PMC: 11417326. DOI: 10.1016/j.invent.2024.100775.

References

Ware Jr J, Kosinski M, Keller S . A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3):220-33. DOI: 10.1097/00005650-199603000-00003. View

Zhang B, Wing Y . Sex differences in insomnia: a meta-analysis. Sleep. 2006; 29(1):85-93. DOI: 10.1093/sleep/29.1.85. View

Thorndike F, Berry R, Gerwien R, Braun S, Maricich Y . Protocol for Digital Real-world Evidence trial for Adults with insomnia treated via Mobile (DREAM): an open-label trial of a prescription digital therapeutic for treating patients with chronic insomnia. J Comp Eff Res. 2021; 10(7):569-581. DOI: 10.2217/cer-2021-0004. View

Edinger J, Arnedt J, Bertisch S, Carney C, Harrington J, Lichstein K . Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2020; 17(2):255-262. PMC: 7853203. DOI: 10.5664/jcsm.8986. View

Qaseem A, Kansagara D, Forciea M, Cooke M, Denberg T . Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016; 165(2):125-33. DOI: 10.7326/M15-2175. View

Fullerton D . The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care. 2006; 12(8 Suppl):S246-52. View

Murtagh D, Greenwood K . Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol. 1995; 63(1):79-89. DOI: 10.1037//0022-006x.63.1.79. View

Kroenke K, Spitzer R, Williams J . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606-13. PMC: 1495268. DOI: 10.1046/j.1525-1497.2001.016009606.x. View

Roth T, Coulouvrat C, Hajak G, Lakoma M, Sampson N, Shahly V . Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep.... Biol Psychiatry. 2011; 69(6):592-600. DOI: 10.1016/j.biopsych.2010.10.023. View

10.

Morin C, Hauri P, Espie C, Spielman A, Buysse D, Bootzin R . Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 2000; 22(8):1134-56. DOI: 10.1093/sleep/22.8.1134. View

11.

Kingsbury J, Buxton O, Emmons K . Sleep and its Relationship to Racial and Ethnic Disparities in Cardiovascular Disease. Curr Cardiovasc Risk Rep. 2013; 7(5). PMC: 3824366. DOI: 10.1007/s12170-013-0330-0. View

12.

Spitzer R, Kroenke K, Williams J, Lowe B . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10):1092-7. DOI: 10.1001/archinte.166.10.1092. View

13.

Stoller M . Economic effects of insomnia. Clin Ther. 1994; 16(5):873-97; discussion 854. View

14.

Edinger J, Arnedt J, Bertisch S, Carney C, Harrington J, Lichstein K . Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2020; 17(2):263-298. PMC: 7853211. DOI: 10.5664/jcsm.8988. View

15.

Morin C . Profile of Somryst Prescription Digital Therapeutic for Chronic Insomnia: Overview of Safety and Efficacy. Expert Rev Med Devices. 2020; 17(12):1239-1248. DOI: 10.1080/17434440.2020.1852929. View

16.

Mitchell M, Gehrman P, Perlis M, Umscheid C . Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012; 13:40. PMC: 3481424. DOI: 10.1186/1471-2296-13-40. View

17.

Zachariae R, Lyby M, Ritterband L, OToole M . Efficacy of internet-delivered cognitive-behavioral therapy for insomnia - A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2015; 30:1-10. DOI: 10.1016/j.smrv.2015.10.004. View

18.

Haghayegh S, Khoshnevis S, Smolensky M, Diller K, Castriotta R . Accuracy of Wristband Fitbit Models in Assessing Sleep: Systematic Review and Meta-Analysis. J Med Internet Res. 2019; 21(11):e16273. PMC: 6908975. DOI: 10.2196/16273. View

19.

Ohayon M . Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2003; 6(2):97-111. DOI: 10.1053/smrv.2002.0186. View

20.

Ozminkowski R, Wang S, Walsh J . The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007; 30(3):263-73. DOI: 10.1093/sleep/30.3.263. View